Day Zero Diagnostics and Oxford Nanopore today announced a collaboration to develop a solution for diagnosing bloodstream infections.
Boston-based Day Zero Diagnostics develops diagnostics utilizing whole-genome sequencing and AI to combat antibiotic-resistant infections. Oxford Nanopore offers a new generation of nanopore-based molecular sensing technology. They seek to enable early detection to combat bloodstream infections as they are a leading cause of sepsis.
The companies plan to integrate and optimize a diagnostic system for use in clinical settings like hospitals. They aim to offer same-day identification and genomic-based antibiotic susceptibility profiling without the need for blood culture. According to a news release, the companies plan to pursue regulatory approvals, including with the FDA, down the line.
In the collaboration, the companies intend to combine Day Zero Diagnostics’ ultra-high enrichment sample preparation technology and …